Implant Sciences get grant for spinal cancer therapy:
This article was originally published in Clinica
Implant Sciences has gained a $750,000 phase II grant from the US National Institutes of Health (NIH) to continue developing and testing its radioactive plaque technology for treating cancers of the thoracic and lumbar spine. Specifically, the plaque is designed to treat the sarcoma cells on the dural surface without subjecting the spinal cord to harmful doses, says the Wakefield, Massachusetts firm. The award will provide funding for over the next 24 months. Improvements will be made to a prototype of radioactive plaque device, and the resulting product will be assessed in a human trial in collaboration with Massachusetts General Hospital.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.